tbuckley/cabot-search huggingface dataset:
Abstract 4496: UBCH10 overexpression in human colorectal cancers
Authors: Salvatore Piscuoglio, Pierlorenzo Pallante, Luigi Tornillo, Alfredo Fusco, Luigi Maria Terracciano
Journal: Cancer Research (2012)

Abstract Background: Colorectal cancer is the result of the accumulation of different genetic modifications including critical genes involved in the control of cell proliferation. In a large number of carcinomas with worst prognosis, lesions are not diagnosed until the disease is at an advanced stage. To diagnose cancer at an early stage and to establish more effective therapies featuring of key molecules in carcinogenesis is a critical steps. UBCH10 (also known as E2C or UBE2C) is a cell cycle-related protein involved in mitosis completion. UbcH10 participates in proper metaphase to anaphase transition, and abrogation of UbcH10 results in the premature separation of sister chromatids. Thus, UbcH10 is essential for cell cycle progression, and his expression is cell-cycle dependent and related to proliferation Aims: The aim of this study is to investigate the association of UbcH10 gene expression with clinicopathological features and tumor progression of colorectal cancer. Materials and methods: We investigated the expression of the UBCH10 genes in a tissue microarray platform consisting of normal and neoplastic colorectal cancers (CRC) tissues by immunohistochemistry. UBCH10 was detectable in 889 patients. Immunoreactivity was scored semi-quantitatively by evaluating the number of positive tumor cells over the total number of tumor cells. Scores were assigned using 5% intervals and ranged from 0% to 100%. Median protein expression levels were used as cut-off scores to define protein marker positivity and the findings were associated with clinical-pathological parameters. Results: Our results demonstrated that UBCH10 is over-expressed in CRCs tissues compared to normal colon (p&amp;lt;0,001), and more specifically the UBCH10 expression is significant higher in tumor location: left VS. right sided (p=0,005). Moreover we found a significant relationship between overexpression of UBCH10 with T stage (p&amp;lt;0,001), N stage (p=0.022), tumor border configuration: pushing VS. infiltrating (p=0.035) and also UBCH10 over-expression was significantly correlated with shorter patient survival. Conclusion: Our study suggests that the overexpression of UbcH10 gene plays a critical role in the carcinogenesis and tumor progression of colorectal cancer. Also our findings indicate, that in colorectal carcinomas, low expression of UBCH10 may be linked to a more aggressive tumor phenotype. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4496. doi:1538-7445.AM2012-4496
Supradiaphragmatic Thoracic-Duct Cyst
Authors: George L. Emerson
Journal: New England Journal of Medicine (1950)

DURING an operation for a posterior mediastinal mass of unknown nature, a cyst of the thoracic duct was found and removed. In a subsequent search for similar cases, none were found in the English literature. The few foreign cases had occurred in older persons, and all were found in postmortem examinations. Although cysts of the cisterna chyli are not particularly uncommon, they very rarely arise within the supradiaphragmatic thoracic duct, especially in young persons.The thoracic duct frequently escapes observation in routine post-mortem examination because of its small caliber and deep position. At present, only 7 cases of thoracic-duct cyst . . .
Government will need to make health policy U turns after Francis report, says safety expert
Authors: Z. Kmietowicz
Journal: BMJ (2013)

Patient safety campaigners have called on the government to accept all the recommendations of the public inquiry into the events at Mid Staffordshire NHS Foundation Trust between 2005 and 2009 when they are published on 6 February, even if this means changing its current policy.

Peter Walsh, chief executive of the patients’ charity Action Against Medical Accidents (AvMA), said that there were some “pretty strong clues” as to what the report was likely to recommend from the closing statements of the inquiry’s chairman, Robert Francis QC, and the counsel to the inquiry, Tom Kark QC.

Many of the recommendations would be “contrary to the current direction of travel of the government,” believes Walsh. In a letter to Jeremy Hunt, the health secretary for England, Walsh asked for “an assurance that you will implement …
Osteoarthritis of the Cervical Spine
Authors: John G. Kuhns
Journal: New England Journal of Medicine (1956)

OSTEOARTHRITIS of the cervical spine, sometimes called cervical discogenic disease, is one of the most common and most troublesome affections of the older arthritic patient. It is found in at least 10 per cent of the patients suffering from osteoarthritis. The symptoms, the clinical findings and the roentgenologic changes vary greatly from patient to patient. However, cervical osteoarthritis can be divided into three stages of progressive degeneration (Table 1). There are no diagnostic or therapeutic criteria for osteoarthritis such as those available in rheumatoid arthritis, but degrees of severity can be recognized.1 StagesThe first and commonest of these stages . . .
CONTEMPORARY DIABETIC CARDIOMYOPATHY IS CHARACTERIZED BY CONCENTRIC REMODELING AND DIASTOLIC DYSFUNCTION - NOT LEFT VENTRICULAR HYPERTROPHY OR SYSTOLIC DYSFUNCTION
Authors: Peter Godsk Jørgensen, Magnus Jensen, Rasmus Mogelvang, Thomas Hansen, Soren Galatius, Tor Biering-Sørensen, Heidi Storgaard, Tina Vilsbøll, Peter Rossing, Jan Jensen
Journal: Journal of the American College of Cardiology (2016)
Abstract 1486: Role of Slug in chemoresistance, invasion and metastasis of CD133-expressing pancreatic cancer.
Authors: Koichirou Tsukasa, Qiang Ding, Makoto Yoshimitsu, Yumi Miyazaki, Toru Obara, Shyuichiro Matsubara, Koki Maeda, Sonshin Takao
Journal: Cancer Research (2013)

Abstract Background: Pancreatic cancer is a devastating disease despite current development of therapy. Accumulating evidence suggests that cancer stem cells (CSCs) are responsible for recurrence and chemoresistance. CD133, a marker of CSCs in various solid tumors including pancreatic cancer, has been studied for recent decade. However, the role of CD133 is still obscure. Epithelial-mesenchymal transition (EMT), which is the essential process in the wound healing, development and cancer progression, is one of the CSC characteristics. However, the role of EMT in the pancreatic cancer progression is not sufficiently elucidated. Slug is a member of the Snail family of zinc finger transcription factors and plays a role in the EMT. Slug is demonstrated to be overexpressed in numerous cancers, and involved in migration and tumorigenesis. Recent study demonstrated that EMT was directly suppressed by downregulation of the transcription of Slug (Chakrabarti et al, Nat Cell Biol, 2012). In this study, we investigated the relationship between Slug and biological properties in pancreatic cancer cells. Materials and Methods: We established a highly migratory cell population with endogenous CD133high derived from Capan-1 cells by migration assay system. Over 90% of CD133high cells expressed CD133 by flow cytometer. Consequently, we established CD133knock-down and Slugknock-down by lentiviral transduction method. We used gemcitabine (GEM) for chemosensitivity assay. To examine the role of Slug, we used migration and invasion assay, wound healing assay, DNA microarray, real-time RT-PCR and Western blot. Results: 1) DNA microarray and real-time RT-PCR revealed higher expression of EMT-related genes, such as Slug and N-cadherin, in CD133high cells compared to CD133knock-down cells, suggesting that CD133knock-down related to downregulation of Slug. 2) Slugknock-down cells showed more sensitive to GEM by MTT assay compared to parental cells (CD133high cells), but no change of CD133 expression. 3) Slugknock-down cells showed less migratory and invasive abilities than CD133high cells. 4) CD133high cells showed more in vivo metastasis compared to CD133knock-down cells using immunodeficient mice. In vivo experiment using Slugknock-down cells is now ongoing. Conclusion: Our results suggest that Slug plays an important role in chemoresistance, invasion and metastasis. Citation Format: Koichirou Tsukasa, Qiang Ding, Makoto Yoshimitsu, Yumi Miyazaki, Toru Obara, Shyuichiro Matsubara, Koki Maeda, Sonshin Takao. Role of Slug in chemoresistance, invasion and metastasis of CD133-expressing pancreatic cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1486. doi:10.1158/1538-7445.AM2013-1486
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study.
Authors: T Aihara, Y Takatsuka, S Osumi, K Aogi, Y Hozumi, S Imoto, H Mukai, H Iwata, T Watanabe, C Shimizu, K Nakagami, M Tamura, T Ito, N Masuda, N Ogino, K Hisamatsu, S Mitsuyama, H Abe, T Yamaguchi, Y Ohashi
Journal: Cancer Research (2009)

Abstract Abstract #1138 Background. Clinical trials conducted in Western countries have shown that improved disease-free survival (DFS) is associated with the use of aromatase inhibitors instead of tamoxifen in postmenopausal women with early breast cancer. Pharmacogenetic differences in drug metabolizing genes may cause ethnic differences in the response or tolerability to aromatase inhibitors, as well as tamoxifen. In fact, improved DFS by extending the use of letrozole after tamoxifen for 5 years has not been confirmed in women from minority groups (Ann Oncol. 2006 17(11):1637-43). Therefore, assessment of the efficacy of aromatase inhibitors in non-white women is warranted. We report the results of switching adjuvant therapy from tamoxifen to anastrozole in postmenopausal Japanese women with breast cancer enrolled in an open-label, randomized clinical trial (N-SAS BC03 study). Patients and Methods. From November 2002 to December 2005, 706 postmenopausal women with hormone-receptor-positive breast cancer who were receiving adjuvant therapy with tamoxifen for 1 to 4 years were randomly assigned to either continue tamoxifen or to switch to anastrozole; the total duration of treatment was 5 years. Primary endpoints were DFS and adverse events. Secondary endpoints included relapse-free survival (RFS), overall survival (OS) and QOL. Results. After a median follow-up of 42 months (range, 3.2-60), there were 26 events in the anastrozole group as compared with 37 in the tamoxifen group related to DFS, and 15 events in the anastrozole group as compared with 28 in the tamoxifen group related to RFS. The unadjusted hazard ratio was 0.69 (95 percent confidence interval, 0.42 to 1.14; P=0.06 by the log-rank test) for DFS and 0.52 (95 percent confidence interval, 0.28 to 0.98; P=0.02 by the log-rank test) for RFS, both in favor of anastrozole. There was no difference in OS (p=0.49). Conclusion. Switching from tamoxifen to anastrozole was confirmed to be associated with a lower disease recurrence rate than continuing tamoxifen in postmenopausal Japanese women with breast cancer. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 1138.
FRI0050 Rosuvastatin Induced Carotid Plaque Regression in Patients with Inflammatory Joint Diseases
Authors: S. Rollefstad, E. Ikdahl, J. Hisdal, I.C. Olsen, K.T. Smerud, G. Kitas, T.R. Pedersen, T.K. Kvien, A.G.P. Semb
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Patients with rheumatoid arthritis (RA) and carotid artery plaques (CP) have increased risk of acute coronary syndrome. Statin treatment with low density lipoprotein cholesterol (LDL-c) goal ≤1.8 mmol/L is recommended for the general population in patients with CP. <h3>Objectives</h3> Our objective was to evaluate the effect of 18 months intensive statin treatment on CP height in patients with inflammatory joint disease (IJD). <h3>Methods</h3> Patients with CP and IJD [RA (n=55), ankylosing spondylitis (n=21) and psoriatic arthritis (n=10)] were treated with rosuvastatin to obtain LDL-c goal. CP height was evaluated by B–mode ultrasound. <h3>Results</h3> The mean age was 60.8±8.5 (mean ± SD) and the gender distribution was 52 (60.5%)/34 (39.5%) [female/male]. Compliance of rosuvastatin usage was 97.9 (96.0, 99.4)[median (IQR)]. At baseline, the median number of CP was 1.0 (1-6) (range), with a median height of 1.80 mm (1.60, 2,10) (IQR). Change in CP height after 18 months on rosuvastatin treatment (mean dose 30.7±14.7 mg) was -0.20±0.34 mm (one-sample t-test, p&lt;0.001). Baseline LDL-c was 4.0±0.9 mmol/L and the change in LDL-c was mmol/L -2.3±0.8 mmol/L (one-sample t-test, p&lt;0.001). Mean LDL-c level during 18 months rosuvastatin treatment was 1.7±0.4 mmol/L. Fifty-three patients (61.6%) achieved LDL-c goal. In a linear regression model (age/gender adjusted) the degree of CP height reduction was independent of the LDL-c level exposure during the study period (p=0.36). Attainment of LDL-c ≤1.8 mmol/L or the change in LDL-c level did not influence degree of CP height reduction (p=0.44 and p=0.46, respectively). In a logistic regression model age, gender, blood pressure and use of biologic medication did not contribute to the CP height reduction. <h3>Conclusions</h3> Intensive lipid lowering with rosuvastatin induced regression of CP height and reduced LDL-c significantly in patients with IJD. The LDL-c goal attainment, the change in LDL-c or the LDL-c level exposure during the study period did not influence the degree of CP height reduction. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.3675
The Disappearance of One Half of a Horseshoe Kidney
Authors: M A Rossleigh, R H Farnsworth
Journal: Clinical Nuclear Medicine (1999)

An infant girl was seen 3 weeks after birth to evaluate her kidneys because of an antenatal ultrasound diagnosis of right hydronephrosis. A postnatal Tc-99m MAG3 study revealed a horseshoe kidney with the right component being smaller than the left. The girl was seen again at 4.5 years with urinary incontinence that involved a constant drip of urine that left her never completely dry. Cystoscopic examination revealed a deficient bladder neck. The left ureteric orifice was located intravesically but the right ureteric orifice ended ectopically at the urethral-vaginal septum. It was unclear whether the child's incontinence resulted from the incompetent bladder neck or from urine draining from the ectopic right ureter, which opened distal to the urethral sphincter. A Tc-99m DMSA study revealed that there was no residual function in the right component of the horseshoe kidney, with only a normal left kidney now seen. The sequence of studies indicated an unusual regression of a hemicomponent of a horseshoe kidney.
AB1074 Hospitalizations and Mortality in Mexican Patients with Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA): Table 1.
Authors: M.U. Martinez Martinez, C.O. Quintero-Martínez, C. Abud-Mendoza
Journal: Annals of the Rheumatic Diseases (2014)

<h3>Background</h3> Survival of rheumatic diseases has been improved over time.<sup>1</sup> Prognosis and causes of death are different between races (Hispanic and African-American SLE patients have worse prognosis than others).<sup>2</sup> <h3>Objectives</h3> To evaluate causes of hospitalization and death in Mexican patients with SLE or RA. Our secondary objective was to compare the mortality of two six-year periods (2001-2006 and 2007-2012). <h3>Methods</h3> In a 12-year period, we evaluate all non-elective hospitalizations with diagnoses of RA or SLE according to the diagnosis registered in our Hospital database (all diagnoses were classified according to the International Classification of Diseases – ICD). We extracted the cause of hospital discharge, sex, age, and demographic factors. We compared the first 6-year period (2001-2006) with a second period (2007-2012). <h3>Results</h3> We included 922 hospitalizations: 449 SLE (48.7%) and 473 (51.3%) RA patients; the twelve-year mortality was 12.5% (n=116). Mortality rate for hospitalizations in the first period (2001-2006) was 13.1 per 100 patient-years (100 PY), and 12.6/100 PY in the second period. The lowest mortality rate was in 2001 (4.4/100 PY) and the highest in 2009 (21.3/100 PY). Mortality among periods was 12.6% of admissions in winter, 10.5% in autumn, 17.0% in spring and 10.8% in summer. Infection was the most frequent cause of death in both RA (37.9%) and SLE (30.8%), followed by cardiovascular disease 15.2% for RA and 5.8% for SLE. Infections were more frequent and cardiovascular diseases more uncommon in 2007 to 2012 (Table 1). <h3>Conclusions</h3> Infections and cardiovascular diseases are the most frequent causes of death in Mexican patients with SLE or RA. Prevention of these morbidities should be a priority. <h3>References</h3> Borchers AT, Keen CL, Shoenfeld Y, Gershwin ME. Surviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus. Autoimmun Rev 2004;3(6):423–53. Pons-Estel GJ, Alarcόn GS. Lupus in Hispanics: a matter of serious concern. Cleve Clin J Med 2012;79(12):824–34. <h3>Disclosure of Interest</h3> None declared <h3>DOI</h3> 10.1136/annrheumdis-2014-eular.4784
Inhibition of Hypoglycemia-Induced Growth Hormone Secretion by the Serotonin Antagonists Cyproheptadine and Methysergide
Authors: Carl H. Bivens, Harold E. Lebovitz, Jerome M. Feldman
Journal: New England Journal of Medicine (1973)

Growth hormone secretion is provoked by hypoglycemia. Since hypothalamic serotonin content increases during insulin-induced hypoglycemia, the role of hypothalamic serotonin in growth hormone secretion in man was examined. Hypoglycemia-induced growth hormone release in normal volunteers was studied during a control period and after two days of administration of serotonin antagonists, cyproheptadine and methysergide. Plasma growth hormone was measured by radioimmunoassay, and total growth hormone secretion was expressed as the area under the growth hormone curve from 0 to 120 minutes. Cyproheptadine administration resulted in a 59 per cent reduction (p<0.01), and methysergide in a 35 per cent reduction (p<0.05) in growth hormone secretion. The decrease in plasma glucose during the control and treatment periods indicated a comparable stimulus for growth hormone release in both study groups. If these drugs act by antagonizing serotonin, as assumed, this study suggests that serotonin is involved in hypoglycemia-induced growth hormone release. (N Engl J Med 289:236–239, 1973)
Abstract P5-07-03: Gallotannins and Gallic acid From Mango Fruit (Mangifera Indica L) Suppress Breast Cancer Tumor Growth by Targeting Phosphatidylinositol3-kinase (PI3K)-Akt-NF-kB Pathway and Associated microRNAs
Authors: N Banerjee, H Kim, K Krenek, S Talcott, SM Talcott
Journal: Cancer Research (2012)

Abstract The cytotoxic and anti-inflammatory properties of polyphenolics have been demonstrated in numerous types of cancer and the objective of this research was to understand the post-transcriptional targets involved in anti-inflammatory and pro-apoptotic pathways in the breast cancer cell line BT474, treated with a polyphenolic extract (2.5–40µg/ml) rich in gallotannins and gallic acid from mango fruit in vitro and in athymic nude mice bearing BT474 cells as xenografts. Results show that cell proliferation as well as tumor size and weight in vivo was decreased by polyphenolics 60% and 70% in vitro and vivo, respectively. NF-kB protein and mRNA expression as well as activation were decreased in a dose-dependent manner (0.6 fold). The extract also inhibited PI3K-dependent phosphorylation of AKT and expression and this was accompanied by down-regulation of miRNA 126 of BT474 (2.25 fold) and in vivo. NFκB-dependent genes involved in apoptosis-inhibition, metastasis and angiogenesis, such as survivin, VCAM-1, and VEGF were also decreased, in vitro and in vivo. A microRNA-array was also used to investigate whether microRNAs with target regions within affected genes were affected by the polyphenolic extract and results show that in addition to miR-126, miR-let-7a and miR-let-7b among others were significantly increased by the extract. In summary the anti-carcinogenic and anti-inflammatory activity of mango polyphenolics in breast cancer cells were at least in part due to targeting miR-126 -Phosphatidylinositol 3-kinase (PI3K)-Akt-NF-kB which plays an important role in the proliferative/ inflammatory phenotype exhibited in this breast cancer cell line. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P5-07-03.
AB0261 Relationship between fatigue and rheumatoid arthritis: results from moroccan quest-ra study
Authors: T. Lakhdar, H. Rkain, F. Znat, S. El Kabbaj, I. Benslama, B. Benchekroun, L. Benbrahim, F. Allali, N. Hajjaj-Hassouni
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> Assessment of fatigue in Moroccan patients with rheumatoid arthritis (RA) and its relationship with disease parameters. <h3>Methods</h3> 1089 Moroccan patients with rheumatoid Arthritis (RA) were included in the multicenter cross-sectional study QUEST-RA (Quantitative Patient Questionnaires in Standard Monitoring of Patients with Rheumatoid Arthritis). The presence of fatigue was researched and its degree was assessed by a visual analogue scale (VAS) ranging from 0 to 100 mm. The presence and intensity of fatigue were correlated to the RA patient and disease parameters (sex, DAS 28, score of Health assessment Questionnaire (HAQ), corticosteroids intake, presence or absence of sleep disorders or psychological problems). <h3>Results</h3> The mean age of our patients was 49 ± 12.6 years with a female predominance of 80.3%. The average of disease duration was 6 (3, 12) years. The mean DAS28 was 4.9 ± 1.68. The average of HAQ was 1 (0.4, 1.6). Fatigue was present in 97.1% patients and the average of VAS fatigue was 43.2 ± 26.6 mm. A high level of fatigue was associated with female gender (44% versus 39%, p = 0.05), an important level of disease activity (r = 0.544, p &lt;0.001), more functional disability (r = 0.660, p &lt;0.001), corticosteroids intake (r = 0.510, p = 0.003), presence of sleep disorders (65.4% versus 36%, p &lt;0.001), and the psychological problems caused by the disease (43.8% versus 21 9%, p &lt;0.001). <h3>Conclusions</h3> Fatigue is a major problem in our patients with RA and must be included in their routine assessment. In our sample, fatigue appears to be related to female sex, high level of disease activity and greater functional disability. <h3>Disclosure of Interest</h3> None Declared
P862 LONGITUDINAL VALIDATION OF BIOMARKERS OF FIBROMAX PANEL, AS SURROGATES FOR DYNAMIC HISTOLOGICAL CHANGES ON LIVER BIOPSY (LB) IN NAFLD PATIENTS
Authors: M. Munteanu, R. Pais, Y. Ngo, F. Charlotte, L. Fedchuk, P. Lebray, P. Bedossa, V. Ratziu, T. Poynard
Journal: Journal of Hepatology (2014)